Who are the key players in the Opdivo (nivolumab) Market Report 2026 market?

Major companies operating in the Opdivo (nivolumab) Market Report 2026 market are Major companies operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical Read More

What are the major opportunities in the Opdivo (nivolumab) market? What are the strategies for the Opdivo (nivolumab) market?

For detailed insights on the major opportunities and strategies in the Opdivo (nivolumab) market, Read More

How does the Opdivo (nivolumab) market relate to the overall economy and other similar markets?

For detailed insights on Opdivo (nivolumab)'s relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Opdivo (nivolumab) market growth? SWOT analysis of the Opdivo (nivolumab) market.

For detailed insights on the key dynamics influencing the Opdivo (nivolumab) market growth and SWOT analysis of the Opdivo (nivolumab) industry, Read More

Opdivo (nivolumab) Market Global Report 2026 Market Report Infographic Image

Item added to cart!

Published : February 2026

Pages :

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Opdivo (nivolumab) Market Report 2026

Name: Opdivo (nivolumab) Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Type (40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL), By Dosage (Injection, Solution, Other Dosages), By Application (Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications), By End-User (Hospitals, Clinics, Other End Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Opdivo (nivolumab) Market Overview

• The Opdivo (nivolumab) market growth in the historic period has been driven by approval of pd-1 inhibitors, rising global cancer burden

• Market expansion is supported by expansion into new oncology indications, growth of combination therapy protocols

• Growth Driver: Impact of Rising Non-Small Cell Lung Cancer Incidence on Opdivo (Nivolumab) Market Growth

• Market Trend: Opdivo (Nivolumab) Market Growth Driven by FDA Approvals for Combination Therapies in NSCLC

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Opdivo (nivolumab) Market?

Opdivo (nivolumab) is a prescription medication that belongs to a class of drugs known as immune checkpoint inhibitors, specifically targeting programmed death-1 (PD-1) receptors. It is a type of immunotherapy used to treat various cancers by enhancing the body's immune system to detect and destroy cancer cells.

The main types in the opdivo (nivolumab) market are 40 mg/4 ml, 100 mg/10 ml, and 240 mg/24 ml. The 40 mg/4 mL dosage of Opdivo is a lower concentration of the drug, designed to be administered to patients requiring a smaller dose, commonly used for specific treatment protocols or lower-weight patients. The various dosages include injection, solution, and others, and several demographics including adult and pediatric. The different applications include melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, classical hodgkin lymphoma (CHL), squamous cell carcinoma of the head and neck (SCCHN), renal cell carcinoma (RCC), and others. The end-users encompass hospitals, clinics, and others.

Opdivo (nivolumab) Market Global Report 2026 Market Report bar graph

What Is The Opdivo (nivolumab) Market Size and Share 2026?

The opdivo (nivolumab) market size has grown strongly in recent years. It will grow from $8.34 million in 2025 to $9.01 million in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to approval of pd-1 inhibitors, rising global cancer burden, limitations of chemotherapy, strong clinical trial outcomes, oncologist adoption of immunotherapy.

What Is The Opdivo (nivolumab) Market Growth Forecast?

The opdivo (nivolumab) market size is expected to see strong growth in the next few years. It will grow to $12.13 million in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to expansion into new oncology indications, growth of combination therapy protocols, increasing biomarker based patient selection, rising cancer diagnosis rates, increased oncology healthcare spending. Major trends in the forecast period include expanding use of immune checkpoint inhibitors, rising adoption of combination immunotherapy regimens, growth in pd-1 based cancer treatments, increased use across multiple cancer indications, focus on long term survival outcomes.

Book your 30 minutes free consultation with our research experts

Global Opdivo (nivolumab) Market Segmentation

1) By Type: 40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL

2) By Dosage: Injection, Solution, Other Dosages

3) By Application: Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications

4) By End-User: Hospitals, Clinics, Other End Users

What Is The Driver Of The Opdivo (nivolumab) Market?

Increasing incidence of non-small lung cancer is expected to propel the growth of the opdivo (nivolumab) market going forward. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. The increasing incidence of non-small cell lung cancer (NSCLC) is primarily attributed to factors such as smoking, exposure to environmental pollutants, genetic mutations, and a family history of cancer. Opdivo works by blocking the PD-1 receptor on immune cells, thereby enhancing the body's immune response to recognize and attack cancer cells. For example, in 2024, the American Cancer Society, a US-based health organization, reported that 234,580 new cases of lung cancer were diagnosed in the US, with 80% of those being non-small cell lung cancer (NSCLC), marking an increase compared to 2023, when 238,340 people were diagnosed with lung cancer. Thus, increasing incidence of non-small lung cancer is driving the growth of the opdivo (nivolumab) industry.

Key Players In The Global Opdivo (nivolumab) Market

Major companies operating in the opdivo (nivolumab) market are Bristol-Myers Squibb, Ono Pharmaceutical

Global Opdivo (nivolumab) Market Trends and Insights

Major companies operating in the opdivo (nivolumab) market are focusing on developing advanced combination therapies to enhance treatment efficacy, overcome resistance mechanisms, and broaden applications across multiple cancer types. Combination therapy refers to the strategic use of Opdivo (nivolumab) alongside other agents, such as chemotherapy, to provide a more comprehensive treatment approach for advanced cancer patients. For instance, in October 2024, the Food and Drug Administration, a US-based federal agency, approved Opdivo (nivolumab) in combination with platinum-doublet chemotherapy as a neoadjuvant treatment, followed by single-agent nivolumab as adjuvant therapy after surgery, for adults with resectable non-small cell lung cancer who do not have known EGFR or ALK mutations. This approval allows Opdivo to be used both before and after surgery, enhancing therapeutic outcomes for eligible patients.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Opdivo (nivolumab) Market?

In June 2024, I-Mab, a US-based biotechnology company focused on developing innovative immunotherapies for cancer, entered into a clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate bispecific antibody givastomig. Through this partnership, I-Mab aims to evaluate its investigational Claudin 18.2 x 4-1BB bispecific antibody, givastomig, in combination with Opdivo (nivolumab) and standard chemotherapy regimens (FOLFOX or CAPOX) as a potential first-line treatment for patients with advanced Claudin 18.2-positive gastric and esophageal cancers. Bristol Myers Squibb is a US-based pharmaceutical company that manufactures Opdivo (nivolumab).

Regional Insights

North America was the largest region in the 0pdivo (nivolumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Opdivo (nivolumab) Market?

The opdivo (nivolumab) market consists of sales of monotherapy and combination therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Opdivo (nivolumab) Market Report 2026?

The opdivo (nivolumab) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the opdivo (nivolumab) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Opdivo (nivolumab) Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$ billion
Revenue Forecast In 2035	$ billion
Growth Rate	CAGR of 8.1% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Type, Dosage, Application, End-User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Bristol-Myers Squibb, Ono Pharmaceutical
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Opdivo (nivolumab) Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Opdivo (nivolumab) Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Opdivo (nivolumab) Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Opdivo (nivolumab) Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Expanding Use Of Immune Checkpoint Inhibitors

4.2.2 Rising Adoption Of Combination Immunotherapy Regimens

4.2.3 Growth In Pd-1 Based Cancer Treatments

4.2.4 Increased Use Across Multiple Cancer Indications

4.2.5 Focus On Long Term Survival Outcomes

5. Opdivo (nivolumab) Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Oncology Clinics

5.3 Cancer Treatment Centers

5.4 Specialty Pharmacies

5.5 Research Institutes

6. Opdivo (nivolumab) Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Opdivo (nivolumab) Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Opdivo (nivolumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Opdivo (nivolumab) Market Size, Comparisons And Growth Rate Analysis

7.3. Global Opdivo (nivolumab) Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Opdivo (nivolumab) Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Opdivo (nivolumab) Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Opdivo (nivolumab) Market Segmentation

9.1. Global Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

40 mg/4 mL, 100 mg/10 mL, 240 mg/24 mL

9.2. Global Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Injection, Solution, Other Dosages

9.3. Global Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Melanoma, Non-small Cell Lung Cancer (NSCLC), Malignant Pleural Mesothelioma, Classical Hodgkin Lymphoma (CHL), Squamous Cell Carcinoma of the Head and Neck (SCCHN), Renal Cell Carcinoma (RCC), Other Applications

9.4. Global Opdivo (nivolumab) Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Clinics, Other End Users

10. Opdivo (nivolumab) Market Regional And Country Analysis

10.1. Global Opdivo (nivolumab) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Opdivo (nivolumab) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Opdivo (nivolumab) Market

11.1. Asia-Pacific Opdivo (nivolumab) Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Opdivo (nivolumab) Market

12.1. China Opdivo (nivolumab) Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Opdivo (nivolumab) Market

13.1. India Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Opdivo (nivolumab) Market

14.1. Japan Opdivo (nivolumab) Market Overview

14.2. Japan Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Opdivo (nivolumab) Market

15.1. Australia Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. South Korea Opdivo (nivolumab) Market

16.1. South Korea Opdivo (nivolumab) Market Overview

16.2. South Korea Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. Western Europe Opdivo (nivolumab) Market

17.1. Western Europe Opdivo (nivolumab) Market Overview

17.2. Western Europe Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. UK Opdivo (nivolumab) Market

18.1. UK Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. Germany Opdivo (nivolumab) Market

19.1. Germany Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. France Opdivo (nivolumab) Market

20.1. France Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. Eastern Europe Opdivo (nivolumab) Market

21.1. Eastern Europe Opdivo (nivolumab) Market Overview

21.2. Eastern Europe Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. North America Opdivo (nivolumab) Market

22.1. North America Opdivo (nivolumab) Market Overview

22.2. North America Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. USA Opdivo (nivolumab) Market

23.1. USA Opdivo (nivolumab) Market Overview

23.2. USA Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Canada Opdivo (nivolumab) Market

24.1. Canada Opdivo (nivolumab) Market Overview

24.2. Canada Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. South America Opdivo (nivolumab) Market

25.1. South America Opdivo (nivolumab) Market Overview

25.2. South America Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Middle East Opdivo (nivolumab) Market

26.1. Middle East Opdivo (nivolumab) Market Overview

26.2. Middle East Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Africa Opdivo (nivolumab) Market

27.1. Africa Opdivo (nivolumab) Market Overview

27.2. Africa Opdivo (nivolumab) Market, Segmentation By Type, Segmentation By Dosage, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. Opdivo (nivolumab) Market Regulatory and Investment Landscape

29. Opdivo (nivolumab) Market Competitive Landscape And Company Profiles

29.1. Opdivo (nivolumab) Market Competitive Landscape And Market Share 2024

29.1.1. Top 10 Companies (Ranked by revenue/share)

29.2. Opdivo (nivolumab) Market - Company Scoring Matrix

29.2.1. Market Revenues

29.2.2. Product Innovation Score

29.2.3. Brand Recognition

29.3. Opdivo (nivolumab) Market Company Profiles

29.3.1. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis

29.3.2. Ono Pharmaceutical Overview, Products and Services, Strategy and Financial Analysis

30. Global Opdivo (nivolumab) Market Competitive Benchmarking And Dashboard

31. Key Mergers And Acquisitions In The Opdivo (nivolumab) Market

32. Opdivo (nivolumab) Market High Potential Countries, Segments and Strategies

32.1 Opdivo (nivolumab) Market In 2030 - Countries Offering Most New Opportunities

32.2 Opdivo (nivolumab) Market In 2030 - Segments Offering Most New Opportunities

32.3 Opdivo (nivolumab) Market In 2030 - Growth Strategies

32.3.1 Market Trend Based Strategies

32.3.2 Competitor Strategies

33. Appendix

33.1. Abbreviations

33.2. Currencies

33.3. Historic And Forecast Inflation Rates

33.4. Research Inquiries

33.5. The Business Research Company

33.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Opdivo (nivolumab) Market, Overview Of Key Products - Product Examples

Table 2: Global Opdivo (nivolumab) Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Opdivo (nivolumab) Market, Supply Chain Analysis

Table 4: Global Opdivo (nivolumab) Market, Major Raw Material Providers

Table 5: Global Opdivo (nivolumab) Market, Major Resource Providers

Table 6: Global Opdivo (nivolumab) Market, Major Manufacturers (Suppliers)

Table 7: Global Opdivo (nivolumab) Market, Major Distributors And Channel Partners

Table 8: Global Opdivo (nivolumab) Market, Key Technologies & Future Trends

Table 9: Global Opdivo (nivolumab) Market, Major Trends

Table 10: Global Opdivo (nivolumab) Market, Major End Users

Table 11: Global Opdivo (nivolumab) Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Opdivo (nivolumab) Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Opdivo (nivolumab) Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Opdivo (nivolumab) Market - TAM, US$ Billion, 2025

Table 15: Global Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Opdivo (nivolumab) Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Opdivo (nivolumab) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Opdivo (nivolumab) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Asia-Pacific, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Asia-Pacific, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Asia-Pacific, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: China, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: China, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: China, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: India, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: India, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: India, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: Japan, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: Japan, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: Japan, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: Australia, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: Australia, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: Australia, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: South Korea, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: South Korea, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: South Korea, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Western Europe, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Western Europe, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Western Europe, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: UK, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: UK, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: UK, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: Germany, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: Germany, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: Germany, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: France, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: France, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: France, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: Eastern Europe, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: Eastern Europe, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: Eastern Europe, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: North America, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: North America, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: North America, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: USA, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: USA, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: USA, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Canada, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: Canada, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: Canada, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: South America, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: South America, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: South America, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Middle East, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Middle East, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Middle East, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Africa, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Africa, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Africa, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Global Opdivo (nivolumab) Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 73: Global Opdivo (nivolumab) Market - Company Scoring Matrix

Table 74: Bristol-Myers Squibb Financial Performance

Table 75: Ono Pharmaceutical Financial Performance

Table 76: Global Opdivo (nivolumab) Market, Competitive Benchmarking (In USD Billions)

Table 77: Global Opdivo (nivolumab) Market, Competitive Dashboard

Table 78: Global Opdivo (nivolumab) Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 79: Global, Opdivo (nivolumab) Market Size Gain ($ Billion), Segmentation By Type, 2025 – 2030

Table 80: Global, Opdivo (nivolumab) Market Size Gain ($ Billion), Segmentation By Dosage, 2025 – 2030

Table 81: Global, Opdivo (nivolumab) Market Size Gain ($ Billion), Segmentation By Application, 2025 – 2030

List Of Figures

Figure 1: Global Opdivo (nivolumab) Market, Overview Of Key Products - Product Examples

Figure 2: Global Opdivo (nivolumab) Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Opdivo (nivolumab) Market, Supply Chain Analysis

Figure 4: Global Opdivo (nivolumab) Market, Major Raw Material Providers

Figure 5: Global Opdivo (nivolumab) Market, Major Resource Providers

Figure 6: Global Opdivo (nivolumab) Market, Major Manufacturers (Suppliers)

Figure 7: Global Opdivo (nivolumab) Market, Major Distributors And Channel Partners

Figure 8: Global Opdivo (nivolumab) Market, Key Technologies & Future Trends

Figure 9: Global Opdivo (nivolumab) Market, Major Trends

Figure 10: Global Opdivo (nivolumab) Market, Major End Users

Figure 11: Global Opdivo (nivolumab) Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Opdivo (nivolumab) Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Opdivo (nivolumab) Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Opdivo (nivolumab) Market - TAM, US$ Billion, 2025

Figure 15: Global Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Opdivo (nivolumab) Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Opdivo (nivolumab) Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Opdivo (nivolumab) Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Asia-Pacific, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Asia-Pacific, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Asia-Pacific, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: China, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: China, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: China, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: India, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: India, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: India, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: Japan, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: Japan, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: Japan, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: Australia, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: Australia, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: Australia, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: South Korea, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: South Korea, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: South Korea, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Western Europe, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Western Europe, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Western Europe, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: UK, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: UK, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: UK, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: Germany, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: Germany, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: Germany, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: France, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: France, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: France, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: Eastern Europe, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: Eastern Europe, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: Eastern Europe, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: North America, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: North America, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: North America, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: USA, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: USA, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: USA, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Canada, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: Canada, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: Canada, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: South America, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: South America, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: South America, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Middle East, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Middle East, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Middle East, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Africa, Opdivo (nivolumab) Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Africa, Opdivo (nivolumab) Market, Segmentation By Dosage, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Africa, Opdivo (nivolumab) Market, Segmentation By Application, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Global Opdivo (nivolumab) Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 73: Global Opdivo (nivolumab) Market - Company Scoring Matrix

Figure 74: Bristol-Myers Squibb Financial Performance

Figure 75: Ono Pharmaceutical Financial Performance

Figure 76: Global Opdivo (nivolumab) Market, Competitive Benchmarking (In USD Billions)

Figure 77: Global Opdivo (nivolumab) Market, Competitive Dashboard

Figure 78: Global Opdivo (nivolumab) Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 79: Global, Opdivo (nivolumab) Market Size Gain ($ Billion), Segmentation By Type, 2025 – 2030

Figure 80: Global, Opdivo (nivolumab) Market Size Gain ($ Billion), Segmentation By Dosage, 2025 – 2030

Figure 81: Global, Opdivo (nivolumab) Market Size Gain ($ Billion), Segmentation By Application, 2025 – 2030

Competitive and Market Trend Analysis of Gastric Cancer Therapy Industry Through 2029

Industry Trends Show Gastrointestinal Therapeutics Market Set to Expand at 5.5% CAGR Until 2029

Key Market Drivers, Trends, and Forecast for the Global Gene-Editing Transfection Chemicals Industry

Outlook for Generic Pharmaceuticals Contract Manufacturing Market: Key Developments and Future Strategies to 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Discover key trends and market dynamics in the Mycobacterium Tuberculosis Market with 2025 insights from The Business Research Company.

Therapeutic Proteins Market Report 2026 - Global Outlook – By Product Type (Insulin, Fusion Protein, Erythropoietin, Interferon, Human Growth Hormone, Follicle Stimulating Hormone ), By Function (Enzymatic And Regulatory...

Protein Sequencing Market Report 2026 - Global Outlook – By Product And Service (Protein Sequencing Products, Protein Sequencing Services), By Application (Bio-Therapeutics, Genetic Engineering, Other Applications), By E...

Protein Extracts From Single Cell Protein And Other Conventional Sources Market Report 2026 - Global Outlook – By Source (Plant Protein Extract Sources, Microbial Sources - Single Cell Proteins, Microbial Sources - Direc...

Research-Grade Proteins Market Report 2026 - Global Outlook – By Product (Cytokines And Growth Factors, Antibodies, Immune Checkpoint Proteins, Virus Antigens, Enzymes, Recombinant Regulatory Proteins, Hormones, Other Pr...

PEGylated Proteins Market Report 2026 - Global Outlook – By Product (Consumable And Services, PEGylation Kits And Reagents, Monofunctional Linear PEGs, Bifunctional PEGs, Other Products), By Protein Type (Colony Stimulat...

Protein Chip Market Report 2026 - Global Outlook – By Product (Lab-On-Chip, Integrated System, Arrays, Microarrays System), By Technology (Analytical Microarrays, Functional Protein Microarrays, Reverse Phase Protein Mic...

Cell Culture Protein Surface Coating Market Report 2026 - Global Outlook – By Coating Type (Pre-Coating, Multiwall Or Microwell Plates, Flasks, Petri Dishes, Slides, Cover Slips, Self-Coating), By Protein Source (Animal-...

Frequently Asked Questions

How big is the Opdivo (nivolumab) Market?

The Opdivo (nivolumab) market was valued at $ billion in 2025, increased to $ billion in 2026, and is projected to reach $ billion by 2030.

What is the Opdivo (nivolumab) market growth?

The global Opdivo (nivolumab) market is expected to grow at a CAGR of 7.7% from 2026 to 2035 to reach $ billion by 2035.

Who are the key players in Opdivo (nivolumab) market?

Some Key Players in the Opdivo (nivolumab) market Include, Bristol-Myers Squibb, Ono Pharmaceutical .

What is the anticipated growth trend for the Opdivo (nivolumab) market?

Major trend in this market includes: Opdivo (Nivolumab) Market Growth Driven by FDA Approvals for Combination Therapies in NSCLC. For further insights on this market. request a sample here

Which region has the most growth potential in the Opdivo (nivolumab) market?

North America was the largest region in the 0pdivo (nivolumab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opdivo (nivolumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.